The study on the preventive effect of irsogladine for gastric bleeding risk of antithrombotic drugs after ESD -multicenter randomized controlled study of irsogladine + PPI versus PPI alone-

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2013
INTERVENTION: rabeprazole 10mg/day p.o. for 8 weeks rabeprazole 10mg/day and irsogladine 4mg/day p.o. for 8 weeks CONDITION: gastric tumor(early gastric cancer, gastric adenoma) PRIMARY OUTCOME: Frequency of gastrointestinal bleeding after ESD INCLUSION CRITERIA: Subjects with gastric tumor who are aged 20 years or older when the written informed consent is obtained
Epistemonikos ID: 72244e128706fbce815af3a8b7b58d1594b671f4
First added on: Aug 22, 2024